Comparison of Ribavirin with PEG-Interferon α-2a or with α-2b in Treatment-Naïve Patients
Amy Webb, Isela Poy, Rikin Patel et al. · The American Journal of Gastroenterology · 2006
Purpose: The standard of care of hepatitis C (HCV) patients is peginterferon (PEG-IFN) in combination with ribavirin. There are competing claims as to which PEG-IFN is superior and better tolerated. One study indicates that α-2b is better in obese patients (Gastro 128: M953, 2005). Methods: To compare outcomes of PEG-IFN α-2a or α-2b in combination with ribavirin in a retrospective study. 507 naïve HCV patients were identified from UTHSCSA and STVHCS between 2001–05. Excluded from the study were decompensated cirrhotics, liver transplant patients and those coinfected with HIV. Included in the multivariable logistic regression models were initial HCV viral load, genotype (GT), fibrosis stage, race, age, gender, BMI and PEG-IFN treatment. Intention-to-treat analysis was used. Outcomes for logistic regression were early treatment discontinuation (EDC) due to side effects, early viral response (EVR) (−2 log in HCV RNA in 12 wks), and sustained viral response (SVR) (HCV RNA<50 IU/ml 24 wks post treatment). Results: There were 513 patients with 163 receiving α-2a and 350 getting α-2b, with no differences in baseline demographics between treatment groups. There were 13% more patients with GT non-1 in the α-2a than in the α-2b arm (p= 0.004). Multivariable logistic regression analysis revealed that GT, race and fibrosis were significant predictors when modeling EVR (p < 0.08) and SVR (p < 0.04). In GT1 patients, there was no difference in EVR (71.4% α-2a vs. 62.8% α-2b, p= 0.16) or SVR (32.0% α-2a vs. 30.3% α-2b, p= 0.78). In GT non-1, there was no difference in EVR (92.9% α-2a vs. 87.1% α-2b, p= 0.22) or SVR (69.1% α-2a vs. 59.1% α-2b, p= 0.18). Gender, BMI, age and HCV RNA counts did not affect outcomes. Degree of weight loss was similar between treatment groups (p= ns). Moreover, EDC due to side effects was similar between the treatment groups (20% α-2a vs 23% α-2b, p= 0.48). Conclusions: PEG-IFN α-2a and α-2b in combination with ribavirin gave comparable efficacy and tolerability in the treatment of naïve HCV patients. We await the results of the prospective, randomized IDEAL study comparing the two pegylated interferons.
Cited by 0 works. doi:10.14309/00000434-200609001-00412